Clinical trials: flow cytometry
Relapsed B-Cell Acute Lymphoblastic Leukemia
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells".
- Trial name
- NCT01860937
- Testing
- leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment.
- Trial name
- CARTROG (NCT06352242)
- Testing
- Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients, Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers
- Where
- 2 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Head and Neck Cancer
Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00690872
- Testing
- autologous Epstein-Barr virus-specific cytotoxic T lymphocytes, carboplatin, gemcitabine hydrochloride
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Purpura, Thrombocytopenic, Idiopathic, Regulatory B Cells
Regulatory B Cells and Chronic Immune Thrombocytopenia
The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells.
- Trial name
- PTIREG (NCT02891109)
- Testing
- Biological tests
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Acute Lymphobkastic Leukemia
Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue.
- Trial name
- NCT06985498
- Testing
- Sandwich stratergy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Male Breast Cancer, Recurrent Breast Cancer
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
RATIONALE: ONTAK may be able to help reduce the type of cells that prevent other types of immune cells from attacking the breast cancer cells.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00425672
- Testing
- ONTAK, flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Breast Cancer
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00436709
- Testing
- bevacizumab, pegfilgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ischemic Stroke
Inflammatory faCtors AfteR acUte Ischemic Stroke
ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke.
- Trial name
- ICARUS (NCT04412187)
- Testing
- [18F]-GE-180 PET, 3T MRI, immune cell profiling in blood
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Martin Dichgans
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma
B-cell Chronic Lymphoid Malignancies Markers
Lymphoid chronic B-cell malignancies are frequent pathologies that affect adults, with a very variable prognosis and treatment (some of them can remain untreated).
- Conditions
- Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia, Mantle Cell Lymphoma
- Trial name
- MALYZOMA-II (NCT04952974)
- Where
- France
- Volunteers
- 420 people
- Sponsor
- University Hospital, Strasbourg, France
Cystinosis, Native Kidney
Cystinosis and Mitochondrial Metabolism
Cystinosis is a monogenic autosomal recessive lysosomal storage disease with complete penetrance, caused by a biallelic mutation in the CTNS gene (17p13.2) encoding cystinosin, a ubiquitous membrane protein whose role is to clear…
- Trial name
- CYSTI-MITO (NCT07319091)
- Testing
- Mitochondrial metabolism
- Where
- 9 sites in France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Hematopoietic Stem Cell Transplantation
Immunomonitoring After Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option for many hematologic malignancies, in particular acute leukemias and myelodysplastic syndromes.
- Trial name
- Allo Monitor (NCT04635397)
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Head and Neck Cancer
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00589186
- Testing
- Ad5F35-LMP1/LMP2-transduced autologous dendritic cells, celecoxib, flow cytometry
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Neoplastic Cells, Circulating
The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in pancreatic cancer could play an important role in…
- Trial name
- NCT02406846
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Healthy Volunteers
Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)
Clinical evaluation of vaccines against respiratory viruses is currently based on the analysis of systemic immune responses, whereas respiratory immunity is the first line of defense against respiratory pathogens.
- Trial name
- MUCOVAC (NCT06469359)
- Testing
- Nasal tissue-resident memory T and B cells, Nasal fluid sampling, Saliva sampling
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Anxiety Disorder, Colorectal Cancer
Moderate Physical Activity in Helping Patients Recover Physically and Emotionally From Stage II Or Stage III Colorectal Cancer
RATIONALE: Physical activity may prevent or lessen depression and anxiety and improve quality of life and immune function in patients with colorectal cancer.
- Conditions
- Anxiety Disorder, Colorectal Cancer, Depression, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00373022
- Testing
- exercise intervention, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Arizona
Kidney Cancer
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00589550
- Testing
- PEG-interferon alfa-2b, Sorafenib, gene expression analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Thomas Olencki
Leukemia
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
RATIONALE: Diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia.
- Trial name
- NCT00005619
- Testing
- polymerase chain reaction, flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Northwestern University
Systemic Lupus Erythematosus
Prediction of Lupus Renal Flares Study
In patients with systemic lupus erythematosus, urinary CD4+ T cells may have the potential to predict subsequent renal flares in the next 6 months.
- Trial name
- NCT05362812
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Charite University, Berlin, Germany
Myeloma Multiple
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
The main aim of this study is to evaluate the effectiveness of the clinical application of the XN-1000/20 hematology analyzer for risk stratification in patients with multiple myeloma based on the number of detected plasma cells…
- Trial name
- NCT04242121
- Testing
- fluorescence flow cytometry
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Ivan S Moiseev